Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection versus EPO for treating renal anemia amongst Indian pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC nephrology 2019-03, Vol.20 (1), p.90-9, Article 90
Hauptverfasser: Sinha, Shubhadeep D, Bandi, Vamsi Krishna, Bheemareddy, Bala Reddy, Thakur, Pankaj, Chary, Sreenivasa, Mehta, Kalpana, Pinnamareddy, Vikranth Reddy, Pandey, Rajendra, Sreepada, Subhramanyam, Durugkar, Santosh
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Anemia
Anemia - blood
Anemia - drug therapy
Anemia - epidemiology
Care and treatment
Chronic kidney failure
Clinical medicine
Darbepoetin alfa
Darbepoetin alfa - administration & dosage
Dialysis
Dose-Response Relationship, Drug
Drug dosages
End-stage renal disease
Epoetin alfa
Erythropoiesis
Erythropoietin
Female
Glycoproteins
Glycosylated hemoglobin
Hematinics - administration & dosage
Hemoglobin
Hemoglobins
Hospitals
Humans
Injection
Injections, Subcutaneous
Kidney diseases
Male
Medical research
Middle Aged
Mortality
Nephrology
Patients
Peritoneal dialysis
Prospective Studies
Renal Dialysis - adverse effects
Renal Dialysis - trends
Renal Insufficiency, Chronic - blood
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - epidemiology
Safety
Treatment Outcome
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Darbepoetin alfa (DA-α) is a long-acting erythropoiesis-stimulating glycoprotein which has half-life three-fold longer than that of Erythropoietin alfa (EPO). The objective of this study was to compare the efficacy and safety of DA-α injection versus EPO for treating renal anemia amongst Indian patients with end-stage renal disease (ESRD) undergoing dialysis. Patients of either gender (aged 18-65 years) with ESRD undergoing dialysis who had hemoglobin (Hb) levels
ISSN:1471-2369
1471-2369
DOI:10.1186/s12882-019-1209-1